Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors

References

• Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471–87. doi:https://doi.org/10.3322/caac.21493
   PubMed Web of Science ®Google Scholar
• Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.:doi:https://doi.org/10.1016/S1470-2045(07)70410-2
   PubMed Web of Science ®Google Scholar
• Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape U-F, Perren A, Rindi G, Ruszniewski P, Antibes Consensus Conference participants, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology. 2017;105(3):201–11. doi:https://doi.org/10.1159/000472254
   PubMedGoogle Scholar
• Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. doi:https://doi.org/10.1001/jamaoncol.2017.0589
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Osamura RY, Kloppel G. WHO Classification of tumours of endocrine organs. 4th ed. Lyon, France: World Health Organization; 2017. p. 355.
   Google Scholar
• Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73(suppl 1):e490s. doi:https://doi.org/10.6061/clinics/2018/e490s
   PubMedGoogle Scholar
• Badawy AA. Modulation of tryptophan and serotonin metabolism as a biochemical basis of the behavioral effects of use and withdrawal of androgenic-anabolic steroids and other image- and performance-enhancing agents. Int J Tryptophan Res. 2018;11:1178646917753422. doi:https://doi.org/10.1177/1178646917753422
   Google Scholar
• Kvols LK. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci. 1994;733:464–70. doi:https://doi.org/10.1111/j.1749-6632.1994.tb17296.x
   PubMedGoogle Scholar
• Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016;10:662. doi:https://doi.org/10.3332/ecancer.2016.662
   PubMedGoogle Scholar
• Altieri B, Barrea L, Modica R, Muscogiuri G, Savastano S, Colao A, Faggiano A. Nutrition and neuroendocrine tumors: An update of the literature. Rev Endocr Metab Disord. 2018;19(2):159–67. doi:https://doi.org/10.1007/s11154-018-9466-z
   PubMed Web of Science ®Google Scholar
• Adaway JE, Dobson R, Walsh J, Cuthbertson DJ, Monaghan PJ, Trainer PJ, Valle JW, Keevil BG. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem. 2016;53(Pt 5):554–60. doi:https://doi.org/10.1177/0004563215613109
   PubMed Web of Science ®Google Scholar
• Al-Risi ES, Al-Essry FS, Mula-Abed WS. Chromogranin A as a biochemical marker for neuroendocrine tumors: a single center experience at Royal Hospital, Oman. Oman Med J. 2017;32(5):365–70. doi:https://doi.org/10.5001/omj.2017.71
   PubMedGoogle Scholar
• Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86(5):858–65. doi:https://doi.org/10.1002/(sici)1097-0142(19990901)86:5 < 858::aid-cncr23 > 3.0.co;2-8
   PubMed Web of Science ®Google Scholar
• Robbins HL, Symington M, Mosterman B, Tranter F, Davies L, Randeva HS, Penedo A, Ferreira C, Darby C, Grammatopoulos D, et al. Effects of intake of breakfast or caffeine‐containing beverages on measurement of circulating chromogranin A in plasma. GastroHep. 2019;1(1):11–21. doi:https://doi.org/10.1002/ygh2.208
   Google Scholar
• NET Patient Foundation. https://www.netpatientfoundation.org/wp-content/uploads/npf_fastinggut_factsheet.pdf.
   Google Scholar
• Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, et al. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. Tumori. 2019;105(2):113–20. doi:https://doi.org/10.1177/0300891618765362
   PubMed Web of Science ®Google Scholar
• Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T, et al. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept. 2013;2013:926295. doi:https://doi.org/10.1155/2013/926295
   PubMedGoogle Scholar
• Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA, ELECT Study Group. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (Elect): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068–80. doi:https://doi.org/10.4158/EP151172.OR
   PubMed Web of Science ®Google Scholar
• Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas. 2011;40(7):987–94. doi:https://doi.org/10.1097/MPA.0b013e31821f66b4
   PubMedGoogle Scholar
• Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SWJ. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest. 2005;28(11 Suppl International):36–42.
   PubMedGoogle Scholar
• Niederle B, Pape U-F, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, Vienna Consensus Conference participants, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–38. doi:https://doi.org/10.1159/000443170
   PubMed Web of Science ®Google Scholar
• Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Manag Res. 2019;11:7537–56. doi:https://doi.org/10.2147/CMAR.S181439
   PubMed Web of Science ®Google Scholar
• Strosberg J, Joish VN, Giacalone S, Perez‐Olle R, Fish‐Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB. TELEPRO: patient-reported carcinoid syndrome symptom improvement following initiation of telotristat ethyl in the real world. The Oncol. 2019;24(11):1446–52. doi:https://doi.org/10.1634/theoncologist.2018-0921
   PubMed Web of Science ®Google Scholar
• Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, et al. Changes in weight associated with telotristat ethyl in the treatment of carcinoid syndrome. Clin Ther. 2018;40(6):952–62. doi:https://doi.org/10.1016/j.clinthera.2018.04.006
   PubMedGoogle Scholar
• Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–24. doi:https://doi.org/10.1158/1078-0432.CCR-16-2743
   PubMed Web of Science ®Google Scholar
• Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. doi:https://doi.org/10.1056/NEJMoa1607427
   PubMed Web of Science ®Google Scholar
• Clement DS, Tesselaar ME, van Leerdam ME, Srirajaskanthan R, Ramage JK. Nutritional and vitamin status in patients with neuroendocrine neoplasms. World J Gastroenterol. 2019;25(10):1171–84. doi:https://doi.org/10.3748/wjg.v25.i10.1171
   PubMed Web of Science ®Google Scholar
• Go VL, Srihari P, Kamerman Burns LA. Nutrition and gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2010;39(4):827–37. doi:https://doi.org/10.1016/j.ecl.2010.08.003
   PubMedGoogle Scholar
• Maasberg S, Knappe-Drzikova B, Vonderbeck D, Jann H, Weylandt KH, Grieser C, Pascher A, Schefold JC, Pavel M, Wiedenmann B, et al. Malnutrition predicts clinical outcome in patients with neuroendocrine neoplasia. Neuroendocrinology. 2017;104(1):11–25. doi:https://doi.org/10.1159/000442983
   PubMed Web of Science ®Google Scholar
• Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, et al. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Rev Pharmacoecon Outcomes Res. 2019;20(5):1–5. doi:https://doi.org/10.1080/14737167.2019.1660646
   Google Scholar
• Laing E, Kiss N, Michael M, Krishnasamy M. Nutritional complications and the management of patients with gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2020;110(5):430–42. doi:https://doi.org/10.1159/000503634
   PubMedGoogle Scholar
• Laing E, Kiss N, Michael M, Gough K, Krishnasamy M. Investigating nutrition-related complications and quality of life in patients with gastroenteropancreatic neuroendocrine tumors: protocol for a mixed-methods prospective study. JMIR Res Protoc. 2018;7(12):e11228. doi:https://doi.org/10.2196/11228
   PubMedGoogle Scholar
• Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991–1002. doi:https://doi.org/10.1016/j.neo.2017.09.002
   PubMed Web of Science ®Google Scholar
• Kim DH. Nutritional issues in patients with cancer. Intest Res. 2019;17(4):455–62. doi:https://doi.org/10.5217/ir.2019.00076
   PubMed Web of Science ®Google Scholar
• Borre M, Dam GA, Knudsen AW, Gronbaek H. Nutritional status and nutritional risk in patients with neuroendocrine tumors. Scand J Gastroenterol. 2018;53(3):284–92. doi:https://doi.org/10.1080/00365521.2018.1430848
   PubMed Web of Science ®Google Scholar
• Gallo M, Muscogiuri G, Pizza G, Ruggeri RM, Barrea L, Faggiano A, Colao A, NIKE Group The management of neuroendocrine tumours: a nutritional viewpoint. Crit Rev Food Sci Nutr. 2019;59(7):1046–57. doi:https://doi.org/10.1080/10408398.2017.1390729
   PubMed Web of Science ®Google Scholar
• Glazer E, Stanko K, Ong E, Guerrero M. Decreased inpatient mortality in obese patients with abdominal nets. Endocr Pract. 2014;20(12):1–20. doi:https://doi.org/10.4158/EP14203.OR
   Google Scholar
• Qureshi SA, Burch N, Druce M, Hattersley JG, Khan S, Gopalakrishnan K, Darby C, Wong JLH, Davies L, Fletcher S, et al. Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study. BMJ Open. 2016;6(5):e010765. doi:https://doi.org/10.1136/bmjopen-2015-010765
   PubMedGoogle Scholar
• Robbins HL, Symington M, Mosterman B, Goodby J, Davies L, Dimitriadis GK, Kaltsas G, Randeva HS, Weickert MO. Supplementation of vitamin D deficiency in patients with neuroendocrine tumors using over-the-counter vitamin D3 preparations. Nutr Cancer. 2018;70(5):748–54. doi:https://doi.org/10.1080/01635581.2018.1470650
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14(23):7798–803. doi:https://doi.org/10.1158/1078-0432.CCR-08-0734
   PubMedGoogle Scholar
• Marrache F, Vullierme MP, Roy C, El Assoued Y, Couvelard A, O'Toole D, Mitry E, Hentic O, Hammel P, Lévy P, et al. Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer. 2007;96(1):49–55. doi:https://doi.org/10.1038/sj.bjc.6603526
   PubMedGoogle Scholar
• Lind A, Wangberg B, Ellegard L. Vitamin D and vitamin B12 deficiencies are common in patients with midgut carcinoid (SI-NET). Eur J Clin Nutr. 2016;70(9):990–4. doi:https://doi.org/10.1038/ejcn.2016.40
   PubMedGoogle Scholar
• Massironi S, Zilli A, Bernasconi S, Fanetti I, Cavalcoli F, Ciafardini C, Felicetta I, Conte D. Impact of vitamin D on the clinical outcome of gastro-entero-pancreatic neuroendocrine neoplasms: report on a series from a single institute. Neuroendocrinology. 2017;105(4):403–11. doi:https://doi.org/10.1159/000456619
   PubMed Web of Science ®Google Scholar
• Motylewska E, Gawronska J, Niedziela A, Melen-Mucha G, Lawnicka H, Komorowski J, Swietoslawski J, Stepien H. Somatostatin analogs and tumor localization do not influence vitamin D concentration in patients with neuroendocrine tumors. Nutr Cancer. 2016;68(3):428–34. doi:https://doi.org/10.1080/01635581.2016.1152387
   PubMed Web of Science ®Google Scholar
• Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RRP. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol. 2005;100(10):2307–14. doi:https://doi.org/10.1111/j.1572-0241.2005.00268.x
   PubMedGoogle Scholar
• Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN. Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. JPEN J Parenter Enteral Nutr. 1984;8(2):153–9. doi:https://doi.org/10.1177/0148607184008002153
   PubMed Web of Science ®Google Scholar
• Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Ad Hoc EWG: Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;22(3):321–36. doi:https://doi.org/10.1016/S0261-5614(02)00214-5
   PubMed Web of Science ®Google Scholar
• Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, GLIM Working Group, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019;38(1):1–9. doi:https://doi.org/10.1016/j.clnu.2018.08.002
   PubMed Web of Science ®Google Scholar
• Allard JP, Keller H, Gramlich L, Jeejeebhoy KN, Laporte M, et al. GLIM criteria has fair sensitivity and specificity for diagnosing malnutrition when using SGA as comparator. Clin Nutr. 2019;39(9):2771–7. doi:https://doi.org/10.1016/j.clnu.2019.12.004
   PubMedGoogle Scholar
• Contreras-Bolivar V, Sanchez-Torralvo FJ, Ruiz-Vico M, Gonzalez-Almendros I, Barrios M, et al. GLIM criteria using hand grip strength adequately predict six-month mortality in cancer inpatients. Nutrients. 2019;11(9):2043. doi:https://doi.org/10.3390/nu11092043
   PubMed Web of Science ®Google Scholar
• World Cancer Research Fund. [accessed 2020 Feb 16]. https://www.wcrf.org/dietandcancer/cancer-prevention-recommendations.
   Google Scholar
• Blanchard CM, Courneya KS, Stein K. American Cancer Society's SCS, II: Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II. JCO. 2008;26(13):2198–204. doi:https://doi.org/10.1200/JCO.2007.14.6217
   PubMed Web of Science ®Google Scholar
• European Society for Clinical Nutrition and Metabolism. https://www.espen.org/guidelines-home/espen-guidelines.
   Google Scholar
• NHS. Food and neuroendocrine tumors. [accessed 2020 Sept 14]. https://tarawhyand.com/wp-content/uploads/2018/07/Food_and_NETs.pdf.
   Google Scholar
• The Carcinoid Cancer Foundation. [accessed 2020 Feb 16]. https://www.carcinoid.org/for-patients/general-information/nutrition/nutritional-concerns-for-the-carcinoid-patient-developing-nutrition-guidelines-for-persons-with-carcinoid-disease/.
   Google Scholar
• Vanhauwaert E, Matthys C, Verdonck L, De Preter V. Low-residue and low-fiber diets in gastrointestinal disease management. Adv Nutr. 2015;6(6):820–7. doi:https://doi.org/10.3945/an.115.009688
   PubMed Web of Science ®Google Scholar
• Brown AC, Rampertab SD, Mullin GE. Existing dietary guidelines for Crohn's disease and ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2011;5(3):411–25. doi:https://doi.org/10.1586/egh.11.29
   PubMed Web of Science ®Google Scholar
• Storhaug CL, Fosse SK, Fadnes LT. Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(10):738–46. doi:https://doi.org/10.1016/S2468-1253(17)30154-1
   PubMed Web of Science ®Google Scholar
• Lips CJ, Lentjes EG, Hoppener JW. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem. 2003;40(Pt 6):612–27. doi:https://doi.org/10.1258/000456303770367207
   PubMedGoogle Scholar
• Skypala IJ, Williams M, Reeves L, Meyer R, Venter C. Sensitivity to food additives, vaso-active amines and salicylates: a review of the evidence. Clin Transl Allergy. 2015;5:34. doi:https://doi.org/10.1186/s13601-015-0078-3
   PubMed Web of Science ®Google Scholar
• Bushra R, Aslam N, Khan AY. Food-drug interactions. Oman Med J. 2011;26(2):77–83. doi:https://doi.org/10.5001/omj.2011.21
   PubMedGoogle Scholar
• American Institute of Cancer. [accessed 2020 Feb 16]. https://www.aicr.org.
   Google Scholar
• Dernini S, Berry EM, Serra-Majem L, La Vecchia C, Capone R, Medina FX, Aranceta-Bartrina J, Belahsen R, Burlingame B, Calabrese G, et al. Med Diet 4.0: the Mediterranean diet with four sustainable benefits. Public Health Nutr. 2017;20(7):1322–30. doi:https://doi.org/10.1017/S1368980016003177
   PubMed Web of Science ®Google Scholar
• Ghisoni E, Casalone V, Giannone G, Mittica G, Tuninetti V, Valabrega G. Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: a single institution experience. WJCO. 2019;10(12):391–401. doi:https://doi.org/10.5306/wjco.v10.i12.391
   Google Scholar
• Granata V, Fusco R, Setola SV, Castelguidone E. d L d, Camera L, Tafuto S, Avallone A, Belli A, Incollingo P, Palaia R, et al. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge. Radiol Oncol. 2019;53(4):373–87. doi:https://doi.org/10.2478/raon-2019-0040
   PubMedGoogle Scholar
• Magi L, Mazzuca F, Rinzivillo M, Arrivi G, Pilozzi E, et al. Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center. J Clin Med. 2019;8(6):910. doi:https://doi.org/10.3390/jcm8060910
   Web of Science ®Google Scholar